GlassScriptPhysician profile
Anthony C Manilla
NPI 1356332480
$3,818.63
in general payments reported to CMS, 2019-2025
13 companies · $996 in 2025
The $996 reported for 2025 was more than what 79% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $15.69 · 2021: $1,378 · 2022: $461 · 2023: $171 · 2024: $203 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022 · Travel and Lodging: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.39 |
| Travel and Lodging | $347.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $2,675.80 | 2019-2025 | |
| Glaxosmithkline, LLC. | $262.57 | 2022-2023 | |
| Optinose US, INC. | $224.98 | 2019-2025 | |
| Alk-Abello, INC | $138.64 | 2019 | |
| Stryker Corporation | $137.28 | 2019-2025 | Audion Et Dilation System |
| Astrazeneca Pharmaceuticals LP | $84.05 | 2019 | |
| Intersect Ent, INC. | $77.99 | 2019 | |
| Genzyme Corporation | $62.35 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $57.10 | 2019-2024 | Dupixent |
| Medtronic, INC. | $41.04 | 2023 | Propel |
| Acclarent, INC | $22.71 | 2024 | Relieva Tract |
| Paratek Pharmaceuticals, INC. | $17.60 | 2025 | Xhance |
| Novartis Pharmaceuticals Corporation | $16.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Manilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.